The initiative is part of the Pharmacy First programme, first introduced in 2024, which allowed pharmacists who hold an independent prescribing qualification to prescribe drugs for sore throat, ...

AI has implications across the value chain in oncology, including in the diagnostics space, where agentic AI is making it easier to access and understand genomic data – an advance with applications in ...

John Tsai is currently CEO of UK biotech Forcefield Therapeutics and a partner at investment group Syncona. Daiichi Sankyo has named John Tsai as its new global head of R&D, replacing Ken Takeshita, ...

This week, 28 th-29 th May, the Veeva R&D and Quality Summit took place in Copenhagen, Denmark. Focused on innovating together, and together advancing the industry, the Summit this year highlighted an ...

The UK's National Screening Committee has concluded its review of prostate cancer screening in the UK, saying that the harms of a large-scale, national programme would outweigh the benefits. The ...

Sudden unexpected death is a terrifying consequence faced by people living with uncontrolled tonic-clonic seizures (TCSs), so ...

Sobi's $1.5 billion takeover of Arthrosi at the end of 2025 has started to pay off, with a positive phase 3 trial for gout ...

Pfizer has signed a strategic-level R&D alliance with Innovent Biologics, worth $10.5 billion and spanning a dozen programmes in oncology, in another sign of China's emergence as a life sciences R&D ...

GSK's antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, can achieve a functional cure in 19% of patients, ...

As clinical research sites come under growing operational pressure, sponsors and CROs are being challenged to rethink how studies are designed and supported. Protocols are becoming more complex.

Bristol Myers Squibb has high hopes for its celmod programme for blood cancers, and a phase 3 readout – for mezigdomide in multiple myeloma – has delivered the goods. The cereblon E3 ligase modulator, ...

ASCO is just around the corner, and as usual, there is a fertile crop of high-profile clinical trials to look out for among the late-breaker presentations. To follow – and in no particular order - are ...